Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 11/20 | 0.46 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | MMP8 | P22894 | 1/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | GLS | O94925 | 1/20 | 0.37 |
| ▸ | CCR5 | P51681 | 1/20 | 0.37 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4875900 | 0.86 | AOC3 (0.52) | AOC3PSMB5 | |
| SCHEMBL4873433 | 0.84 | AOC3 (0.56) | AOC3CYP17A1MAPK14GLS | |
| SCHEMBL27633589 | 0.84 | AOC3 (0.51) | AOC3CYP17A1MAPK14GLS | |
| SCHEMBL5998880 | 0.82 | AOC3 (0.51) | AOC3 | |
| SCHEMBL6393093 | 0.79 | CYP17A1 (0.45) | AOC3CYP17A1MMP1MMP2MMP9 | |
| SCHEMBL14019611 | 0.75 | AOC3 (0.60) | AOC3 | |
| SCHEMBL4866979 | 0.72 | AOC3 (0.55) | AOC3 | |
| SCHEMBL4872960 | 0.72 | AOC3 (0.55) | AOC3CYP17A1MAPK14GLS | |
| SCHEMBL4866969 | 0.71 | AOC3 (0.55) | AOC3CYP17A1MAPK14GLS | |
| SCHEMBL4876184 | 0.71 | AOC3 (0.49) | AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442715-B2 | Thiazole derivatives | ASTELLAS PHARMA INC. (JP) | 2008-10-28 | — | — | US | disclosed |
| US-20060276521-A1 | Thiazole derivatives | ASTELLAS PHARMA INC. (JP) | 2006-12-07 | — | — | US | disclosed |
| US-20060229346-A1 | Method for treating vascular hyperpermeable disease | SUCAMPO AG (CH) | 2006-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276521-A1 | Thiazole derivatives | VCAM1, ICAM1, TXNL1 | AOC3 782/4885CYP17A1 3237/4885MMP1 510/4885 |
| US-20060229346-A1 | Method for treating vascular hyperpermeable disease | VCAM1, VAPB, ICAM1 | AOC3 85/4885CYP17A1 3226/4885MMP1 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.